Objective: To examine the association between serum matrix metalloproteinases-9 (MMP-9) levels and prognosis of acute ischemic stroke.
Matrix metalloproteinases (MMPs), a group of proteolytic zinc-dependent enzymes, are implicated in various pathophysiology processes such as systemic inflammation, atherosclerosis, and CNS diseases. 1, 2 Among MMPs, MMP-9 (gelatinase B, 92-kDa collagenase) is the most widely investigated enzyme in acute ischemic stroke, and its expression is rapidly upregulated after cerebral ischemia. 3, 4 Aberrant MMP-9 activity may weaken the plaque fibrous cap and play a pivotal role in the proteolytic degradation of the blood-brain barrier. 5, 6 Some clinical studies have suggested that circulating levels of MMP-9 had a significant correlation with disease severity and infarct volume in the hyperacute phase 7, 8 and late hemorrhagic infarction between days 5 and 7 after stroke onset. 9 Despite this, there is limited research on the effect of serum MMP-9 in the acute phase of ischemic stroke on functional outcome or mortality.
Risk stratification among patients with acute ischemic stroke may be useful in helping to select therapeutic strategies. Large sample sizes and well-designed prospective studies on the potential relationship between serum MMP-9 levels and clinical outcomes of acute ischemic stroke are needed. The objectives of this study were to prospectively investigate the association between serum MMP-9 levels and prognosis in patients with acute ischemic stroke using data from the China Antihypertensive Trial in Acute Ischemic Stroke (CATIS).
METHODS Study participants. This study was conducted among patients from the CATIS trial, a multicenter randomized clinical trial conducted in 26 hospitals across China from August 2009 to August 2013. The design and results of CATIS have been described previously. 10 Briefly, 4,071 patients $22 years of age who had first-ever ischemic stroke, confirmed by CT or MRI of the brain within 48 hours of symptom onset, and who had an elevated systolic blood pressure (BP) between 140 and ,220 mm Hg were recruited. Patients with a BP $220/120 mm Hg, severe heart failure, acute myocardial infarction or unstable angina, atrial fibrillation, aortic dissection, cerebrovascular stenosis, or resistant hypertension; those in a deep coma; and those who were treated with intravenous thrombolytic therapy were excluded from the CATIS trial. Because several patients refused to offer blood samples, some collected samples were hemolyzed in storage or transport, or we failed to determine hours of patients' hospital admission. Serum samples were separated at clinical laboratories of the participating hospitals and immediately frozen at 2808C. Serum MMP-9 concentrations were measured centrally at Soochow University with a commercially available ELISA kit (R&D Systems, Minneapolis, MN). Intra-assay and interassay coefficients of variation were 2.0% and 6.9%, respectively. Laboratory technicians who measured MMP-9 were blinded to the clinical outcomes of patients. Baseline data on demographic characteristics, lifestyle risk factors, medical history, and use of medications were collected at hospital admission with a standard questionnaire. Stroke severity was assessed with the NIH Stroke Scale (NIHSS) by trained neurologists at admission. 11 Three BP measurements were also obtained at admission by trained nurses using a standard mercury sphygmomanometer according to a standard protocol adapted from procedures recommended by the American Heart Association. 12 In addition, serum lipids, plasma glucose, and other clinical laboratory measurements were obtained at the participating hospitals at admission.
Study outcomes. Participants were followed up in person at 3 months by trained neurologists unaware of treatment assignment. A combination of death and major disability (modified Rankin Scale [mRS] score $3) was used to measure stroke prognosis. Scores on the mRS range from 0 to 6, with a score of 0 indicating no symptoms, a score of 5 indicating severe disability (i.e., bedridden, incontinent, or requiring constant nursing care and attention), and a score of 6 indicating death. Additional outcomes include death, major disability, and vascular diseases (e.g., vascular death, nonfatal stroke, nonfatal myocardial infarction, hospitalized and treated angina, hospitalized and treated congestive heart failure, and hospitalized and treated peripheral arterial disease). We further included an ordered 7-level categorical score of the mRS as an outcome of neurologic functional status. Death certificates were obtained for deceased participants, and hospital data were abstracted for all vascular events. The study outcomes assessment committee, blinded to treatment assignment, reviewed and adjudicated subsequent outcomes using the criteria established in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Table 2 ORs (95% CIs) of clinical outcomes according to quartiles of serum MMP-9 in the acute phase of ischemic stroke MMP-9, ng/mL Abbreviations: CI 5 confidence interval; MMP-9 5 matrix metalloproteinase-9; mRS 5 modified Rankin Scale; OR 5 odds ratio. a Adjusted for age, sex, time from onset to randomization, current smoking, alcohol drinking, admission NIHSS score, diastolic blood pressure, plasma glucose, white blood cell counts, use of antihypertensive medications, and history of hypertension, coronary heart disease, and diabetes mellitus.
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Statistical analysis. All participants were classified according to quartiles of serum MMP-9 levels, and baseline characteristics were compared among quartiles. Categorical and ordinal logistic regression was used to estimate the risk of clinical outcomes associated with MMP-9 levels. Odds ratios (ORs) and 95% confidence intervals (CIs) for higher quartiles compared to the lowest quartile and for 1-SD increment of log-transformed serum MMP-9 levels were calculated. The covariates included in the multivariable model were age, sex, time from onset to randomization, current smoking, alcohol drinking, diastolic BP, fasting plasma glucose, white blood cell counts, admission NIHSS score, use of antihypertensive medications, and history of hypertension, coronary heart disease, and diabetes mellitus. Tests for linear trends in ORs across MMP-9 quartiles were conducted with the median within each quartile used as the predictor. In addition, we used restricted cubic splines to examine the shape of the association between MMP-9 and stroke prognosis with 4 knots (at the 5th, 35th, 65th, and 95th percentiles). 13 A receiver operating characteristic curve was configured to establish cutoff points of serum MMP-9 levels that optimally predicted clinical outcome. To test the robustness of our findings, we conducted several sensitivity analyses. Randomized treatment was first included in the multivariable models to control for the effect of immediate BP reduction during hospitalization. Because using antihypertensive medications or lipid-lowering drugs before stroke onset might affect MMP-9 levels, we repeated our aforementioned analysis by excluding patients using these drugs before stroke onset. We also performed a sensitivity analysis by multiple imputation of missing MMP-9 values to assess the impact of these missing data.
Because previous studies have reported that circulating MMP-9 levels were associated with several stroke-related risk factors (i.e., cigarette smoking, alcohol consumption, hypertension, coronary heart disease, and diabetes mellitus), [14] [15] [16] [17] [18] [19] we assessed the potential effect modification by these covariables. Interactions between serum MMP-9 levels and covariables on clinical outcomes were tested by the likelihood ratio test of models with interaction terms, with adjustment for the aforementioned covariates. The effect of immediate BP lowering on prognosis across MMP-9 quartiles was also examined with interaction terms. In addition, C statistics, net reclassification index, and integrated discrimination improvement were used to evaluate the incremental prognostic value of serum MMP-9 levels beyond conventional risk factors. 20, 21 All p values were 2 tailed, and a significance level of 0.05 was used. Statistical analysis was conducted with SAS statistical software (version 9.2, Cary, NC).
RESULTS Baseline characteristics. There were 3,186 patients (2,008 men and 1,178 women) with a mean age of 62.4 years included in our study. The median serum MMP-9 concentration was 671.8 ng/mL (interquartile range 414.7-1,025.8 ng/mL). Compared with study participants with lower serum MMP-9 levels, those with higher MMP-9 were more likely to be younger, male, cigarette smokers, and alcohol drinkers; to have a higher prevalence of embolic stroke; to have higher admission diastolic BP, white blood cell count, NIHSS score, and mRS score; and to have shorter time from onset to randomization (table 1) .
Serum MMP-9 levels and clinical outcomes. During 3 months of follow-up, 65 participants (2.0%) were lost to follow-up. Among the remaining participants, 767 participants (24.6%) experienced major disability or died (683 major disability and 84 deaths) (tables 2 and 3). The adjusted OR for the highest vs lowest quartile of MMP-9 was 1.35 (95% CI 1.04-1.76) for the combined outcome after adjustment for age, sex, diastolic BP, fasting plasma glucose, and other covariates. Each 1-SD higher log-transformed MMP-9 was associated with a 16% (OR 1.16, 95% CI 1.06-1.28) increased risk for the combined Table 3 Reclassification and discrimination statistics for 3-month clinical outcomes by serum MMP-9 among patients with acute ischemic stroke showed a linear association between MMP-9 levels and the combined outcome (P for linearity 5 0.003) and major disability (P for linearity 5 0.034) ( figure  1 ). An optimal MMP-9 cut point level (812.2 ng/ mL) was obtained from the receiver operating characteristic curve, and after adjustment for several covariates, elevated MMP-9 levels were associated with the combined outcome (OR 1.29, 95% CI 1.07-1.56, p 5 0.008). There was a dose-dependent relationship between serum MMP-9 levels and 3-month mRS score (p for trend ,0.001) (figure 2 and table e-2).
Sensitivity and subgroup analyses. Further adjustment for the randomized treatment in the multivariable model, exclusion of patients using antihypertensive medications or lipid-lowering drugs before stroke onset, and multiple imputation of missing MMP-9 values did not change the association between MMP-9 and clinical outcomes (table e-3). In subgroup analyses stratified by prespecified factors, serum MMP-9 levels were associated with increased risk of the combined outcome in most strata (table e-4). No significant interaction between serum MMP-9 levels and these covariables on the combined clinical outcome was observed (p for interaction .0.05 for all).
Incremental prognostic value of MMP-9. We examined whether adding serum MMP-9 to conventional risk factors improved the risk prediction of prognosis after acute ischemic stroke. Adding serum MMP-9 to a model containing conventional risk factors did not significantly improve discriminatory power but did significantly improve risk reclassification for the combined outcome (continuous net reclassification index was 9.1% [p 5 0.033] and integrated discrimination improvement was 0.4% [p 5 0.004]).
Effect of immediate BP reduction. Figure e-1 shows no evidence of heterogeneity in the effects of immediate BP reduction on study outcomes at 3 months across quartiles of serum MMP-9 (p for interaction .0.1 for all).
DISCUSSION In this prospective study among the CATIS patients, we observed dose-response associations between higher MMP-9 levels in acute ischemic stroke and increased risk of major disability and death after adjustment for other established covariates. Sensitivity and subgroup analyses further confirmed these findings. To the best of our knowledge, this is the first study to report that higher serum MMP-9 levels are associated with major disability and death among patients with acute ischemic stroke. Data on the effect of serum MMP-9 levels in patients with acute ischemic stroke on poor prognosis Figure 1 Association of serum MMP-9 with risk of death and major disability among patients with acute ischemic stroke
ORs and 95% confidence intervals derived from restricted cubic spline regression, with knots placed at the 5th, 35th, 65th, and 95th percentiles of the distribution of serum MMP-9. Reference point for serum MMP-9 is the midpoint (271.0 ng/mL) of the reference group from categorical analysis. ORs were adjusted for age, sex, time from onset to randomization, cigarette smoking, alcohol drinking, admission NIH Stroke Scale score, diastolic blood pressure, fasting plasma glucose, white blood cell counts, use of antihypertensive medications, and history of hypertension, coronary heart disease, and diabetes mellitus. (A) Combined outcome, (B) major disability, and (C) death. MMP 5 matrix metalloproteinase-9; OR 5 odds ratio.
are sparse. [22] [23] [24] Ning et al. 22 reported that MMP-9 levels measured in the hyperacute phase were correlated to mRS at 3 months (Spearman r 5 0.58, p 5 0.0005) among 52 consecutive ischemic stroke patients. In another study, MMP-9 values at day 7 were positively correlated with mRS score at the 3-month follow-up. 23 A retrospective study based on 844 hemispheric ischemic stroke patients indicated that plasma MMP-9 was associated with poor neurologic outcome (mRS score .3) at 3 months. 24 However, these studies all had small sample sizes or were conducted retrospectively. Our study is a prospective cohort study among participants from the CATIS trial with a large sample size and sufficient statistical power. In addition, standardized protocols and rigid quality control procedures were used for data collection and outcome assessment. Furthermore, comprehensive information about potential confounders was collected and controlled for in the multivariate models. The present study provides a more valid appraisal of the relationship between serum MMP-9 levels and prognosis among patients with acute ischemic stroke.
In the present study, we found that higher serum MMP-9 in acute ischemic stroke was significantly associated with poor outcomes and that the addition of serum MMP-9 to conventional risk factors improves risk prediction for death or major disability. This study has clinical implications for better understanding the etiology of ischemic stroke. Evidence indicates that several inhibitors of MMPs during acute phases of stroke improve neurologic outcomes. [25] [26] [27] It is of clinical interest to see whether MMP-9 reduction with specific inhibitors in the acute phase would improve both short-and long-term prognosis of ischemic stroke.
The mechanisms underlying the observed association of serum MMP-9 with poor prognosis are unclear, although several potential pathophysiologic mechanisms have been proposed. Elevated expression of MMP-9 may reduce the capability to withstand high shear stress at the plaque shoulder region, leading to rupture of the plaque cap. 2, 5 Moreover, experimental studies suggest that oxidative stress is also implicated in the activation of MMP-9 and blood-brain barrier injury, potentially causing adverse outcome. 6, 28 Furthermore, in human studies, circulating MMP-9 has been found to be correlated with stroke severity and infarct volume, as well as being a strong predictor of cerebral edema and hemorrhagic transformation, especially in patients treated with recombinant tissue plasminogen activator. 8, 29 However, Zhao et al. 30 suggested that MMP-9 might have beneficial roles during the delayed phase of stroke progression. Their study showed that MMPs participated in delayed cortical responses after focal cerebral ischemia in rats and that treatment with MMP inhibitors at 7 days after stroke suppressed neurovascular remodeling, increased ischemic brain injury, and impaired functional recovery at 14 days. Therefore, studies of the timedependent effect of MMP-9 on prognosis after stroke are warranted.
Our study has several limitations. First, this study is an observational study among participants from CATIS, a randomized clinical trial. The trial excluded ischemic stroke patients with BP $220/120 mm Hg or treated with intravenous thrombolytic therapy at admission. Therefore, generalizability might be a concern. However, the proportion of patients with BP $220/120 mm Hg or treated with intravenous thrombolytic therapy is low in China, 10, 31 and baseline characteristics of participants in this study were similar to those from the China National Stroke Registry. 32 Second, the possibility of residual confounding cannot be fully eliminated in an observational study, although several important potential confounders have been controlled for in multivariableadjusted models. Third, because all the patients were from China, the findings should be extrapolated cautiously to other populations. Further prospective studies conducted among different populations are needed to replicate our findings. Moreover, 885 patients were excluded for no MMP-9 measurements. This may further limit the generalizability of our findings. However, most baseline characteristics were well balanced between the 2 groups, and a further sensitivity analysis by multiple imputation of missing MMP-9 values found that the significant associations remained. Finally, serum MMP-9 levels were measured only once in this study. Therefore, we were unable to study the diurnal variation of MMP-9 among patients with acute ischemic stroke or the association between MMP-9 changes and prognosis of acute ischemic stroke. Serum MMP-9 and 3-month mRS score
Adjusted odds ratio of ordinal logistic regression analysis is 1.36 (95% confidence interval 1.13-1.64, p for trend ,0.001) for highest vs lowest quartile of serum MMP-9. MMP 5 matrix metalloproteinase-9; mRS 5 modified Rankin Scale.
Our results indicate that higher serum MMP-9 levels in acute ischemic stroke were associated with increased risk of mortality and major disability at 3 months. Serum MMP-9 may act as a potential prognostic marker for initial risk stratification in patients with acute ischemic stroke.
